Found: 45
Select item for more details and to access through your institution.
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
- Published in:
- Diabetes Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1007/s13300-015-0104-4
- By:
- Publication type:
- Article
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 459, doi. 10.1007/s13300-014-0082-y
- By:
- Publication type:
- Article
Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment.
- Published in:
- Diabetes Therapy, 2013, v. 4, n. 2, p. 257, doi. 10.1007/s13300-013-0027-x
- By:
- Publication type:
- Article
Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin.
- Published in:
- Diabetes Therapy, 2012, v. 3, n. 1, p. 1, doi. 10.1007/s13300-012-0008-5
- By:
- Publication type:
- Article
Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.
- Published in:
- Diabetes Therapy, 2011, v. 2, n. 2, p. 51, doi. 10.1007/s13300-010-0018-0
- By:
- Publication type:
- Article
Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction.
- Published in:
- European Heart Journal, 2022, v. 43, n. 23, p. 2224, doi. 10.1093/eurheartj/ehac103
- By:
- Publication type:
- Article
Effect of vildagliptin on hepatic steatosis.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2011, v. 96, n. 4, p. 945, doi. 10.1210/jc.2010-2178
- By:
- Publication type:
- Article
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2009, v. 94, n. 4, p. 1236, doi. 10.1210/jc.2008-215
- By:
- Publication type:
- Article
Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2008, v. 93, n. 1, p. 103, doi. 10.1210/jc.2007-1639
- By:
- Publication type:
- Article
The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2007, v. 92, n. 11, p. 4165, doi. 10.1210/jc.2006-1932
- By:
- Publication type:
- Article
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2004, v. 89, n. 5, p. 2078, doi. 10.1210/jc.2003-031907
- By:
- Publication type:
- Article
Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT‐HF.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 6, p. 818, doi. 10.1002/ejhf.2833
- By:
- Publication type:
- Article
Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 1, p. 43, doi. 10.1002/ejhf.2708
- By:
- Publication type:
- Article
Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 6, p. 1020, doi. 10.1002/ejhf.2508
- By:
- Publication type:
- Article
Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 4, p. 645, doi. 10.1002/ejhf.2431
- By:
- Publication type:
- Article
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry.
- Published in:
- European Journal of Heart Failure, 2015, v. 17, n. 5, p. 527, doi. 10.1002/ejhf.262
- By:
- Publication type:
- Article
The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in Candida albicans.
- Published in:
- Molecular Microbiology, 2000, v. 38, n. 3, p. 435, doi. 10.1046/j.1365-2958.2000.02132.x
- By:
- Publication type:
- Article
Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*.
- Published in:
- Journal of Diabetes, 2012, v. 4, n. 2, p. 181, doi. 10.1111/j.1753-0407.2011.00168.x
- By:
- Publication type:
- Article
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.
- Published in:
- International Journal of Endocrinology, 2015, p. 1, doi. 10.1155/2015/484231
- By:
- Publication type:
- Article
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
- Published in:
- Vascular Health & Risk Management, 2014, v. 10, p. 661, doi. 10.2147/VHRM.S73608
- By:
- Publication type:
- Article
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan.
- Published in:
- 2014
- By:
- Publication type:
- journal article
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
- Published in:
- 2014
- By:
- Publication type:
- journal article
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
- Published in:
- Vascular Health & Risk Management, 2014, v. 10, p. 319, doi. 10.2147/VHRM.S64038
- By:
- Publication type:
- Article
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan.
- Published in:
- Vascular Health & Risk Management, 2014, v. 10, p. 15, doi. 10.2147/VHRM.S54585
- By:
- Publication type:
- Article
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
- Published in:
- Vascular Health & Risk Management, 2013, v. 9, p. 57, doi. 10.2147/VHRM.S40972
- By:
- Publication type:
- Article
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetesand severe renal impairment.
- Published in:
- Vascular Health & Risk Management, 2013, v. 9, p. 21, doi. 10.2147/VHRM.S39300
- By:
- Publication type:
- Article
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
- Published in:
- Vascular Health & Risk Management, 2012, v. 8, p. 339, doi. 10.2147/VHRM.S31758
- By:
- Publication type:
- Article
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
- Published in:
- Vascular Health & Risk Management, 2011, v. 7, p. 49, doi. 10.2147/VHRM.S16925
- By:
- Publication type:
- Article
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
- Published in:
- Vascular Health & Risk Management, 2008, v. 4, n. 3, p. 481
- By:
- Publication type:
- Article
Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2002, v. 18, n. 6, p. 484, doi. 10.1002/dmrr.324
- By:
- Publication type:
- Article
Management of Type 2 Diabetes in Treatment-Naive Elderly Patients.
- Published in:
- Diabetes Care, 2007, v. 30, n. 12, p. 3017, doi. 10.2337/dc07-1188
- By:
- Publication type:
- Article
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2007, v. 30, n. 2, p. 217, doi. 10.2337/dc06-1815
- By:
- Publication type:
- Article
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1 Year.
- Published in:
- Diabetes Care, 2005, v. 28, n. 8, p. 1936, doi. 10.2337/diacare.28.8.1936
- By:
- Publication type:
- Article
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
- Published in:
- Diabetologia, 2015, v. 58, n. 9, p. 2020, doi. 10.1007/s00125-015-3655-z
- By:
- Publication type:
- Article
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
- Published in:
- Diabetologia, 2014, v. 57, n. 7, p. 1304, doi. 10.1007/s00125-014-3222-z
- By:
- Publication type:
- Article
Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
- Published in:
- European Journal of Preventive Cardiology, 2022, v. 29, n. 9, p. 1361, doi. 10.1093/eurjpc/zwac025
- By:
- Publication type:
- Article